Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 13/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 13/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.44 |
| ▸ | ITGAL | P20701 | 2/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12584942 | 0.83 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1PSMB8ALOX5 | |
| SCHEMBL30895880 | 0.82 | CTSD (0.52) | PDE7AMAPTTSHRKMT2AITGB2 | |
| SCHEMBL19840432 | 0.82 | CTSD (0.52) | PDE7AMAPTTSHRKMT2AITGB2 | |
| SCHEMBL12584930 | 0.79 | PDE7A (0.52) | PDE7AMAPTKMT2AALOX5ALDH1A1 | |
| SCHEMBL2031038 | 0.71 | APP (0.52) | PDE7AMAPTKMT2AITGB2ICAM1 | |
| SCHEMBL2032205 | 0.71 | PPARA (0.46) | PDE7AMAPTTSHRKMT2AITGB2 | |
| SCHEMBL2035992 | 0.71 | ILK (0.42) | PDE7AHSP90AA1MAPTTSHRKMT2A | |
| SCHEMBL7187676 | 0.70 | ITGB2 (0.80) | PDE7AMAPTTSHRKMT2AITGB2 | |
| SCHEMBL9676001 | 0.69 | PSMB8 (0.56) | HSP90AA1HSP90AB1MAPTPSMB8ALOX5 | |
| SCHEMBL21794477 | 0.68 | APP (0.57) | MAPTKMT2APSMB8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968567-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968567-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | AMGEN INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | AMGEN INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7626033-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7626033-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | PPARG, PPARA, PPARD | PDE7A 634/4885HSP90AA1 401/4885HSP90AB1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.